abstract |
The present invention relates to means and methods for determining whether a patient is in need of a PD-L1 inhibitor combination therapy. In a patient-derived sample, when it is measured in vitro that ER is non-expressed or expressed at a low level, and the expression level of programmed death ligand 1 (PD-L1) is increased compared to the control, The patient is determined to be in need of PD-L1 inhibitor combination therapy. The patient is receiving treatment comprising a modulator of the HER2 / neu (ErbB2) signaling pathway (such as trastuzumab) and a chemotherapeutic agent (such as docetaxel) or such treatment is planned for the patient . Also, herein, cancer is treated in a cancer patient for whom a treatment comprising a modulator of the HER2 / neu (ErbB2) signaling pathway (such as trastuzumab) and a chemotherapeutic agent (such as docetaxel) is planned. Means and methods are provided, and the patient will receive a combination therapy with a PD-L1 inhibitor. [Selection] Figure 1 |